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Abstract
The records of 208.777 (100%) clinical trials registered at ClinicalTrials.gov were downloaded on the 19th of February 2016.
Phase II and III trials including patients with glioblastoma were selected for further classification and analysis. Based on the
disease settings, trials were classified into three groups: newly diagnosed glioblastoma, recurrent disease and trials with
no differentiation according to disease setting. Furthermore, we categorized trials according to the experimental
interventions, the primary sponsor, the source of financial support and trial design elements. Trends were evaluated
using the autoregressive integrated moving average model. Two hundred sixteen (0.1%) trials were selected for further
analysis. Academic centers (investigator initiated trials) were recorded as primary sponsors in 56.9% of trials, followed by
industry 25.9%. Industry was the leading source of monetary support for the selected trials in 44.4%, followed by 25%
of trials with primarily academic financial support. The number of newly initiated trials between 2005 and 2015 shows a
positive trend, mainly through an increase in phase II trials, whereas phase III trials show a negative trend. The
vast majority of trials evaluate forms of different systemic treatments (91.2%). In total, one hundred different
molecular entities or biologicals were identified. Of those, 60% were involving drugs specifically designed for
central nervous system malignancies. Trials that specifically address radiotherapy, surgery, imaging and other
therapeutic or diagnostic methods appear to be rare. Current research in glioblastoma is mainly driven or sponsored by
industry, academic medical oncologists and neuro-oncologists, with the majority of trials evaluating forms of systemic
therapies. Few trials reach phase III. Imaging, radiation therapy and surgical procedures are underrepresented in current
trials portfolios. Optimization in research portfolio for glioblastoma is needed.
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Introduction
Glioblastoma is the most common and aggressive primary
parenchymal brain tumor [1, 2]. The current standard of
care is based on maximal safe surgical resection followed
by concurrent chemoradiation (CTRT) with temozolomide
followed by six months of maintenance chemotherapy,
resulting in median survival rates of approximately
15 months [3]. Other than temozolomide, only few
agents have shown a clinical benefit to treatment with
radiotherapy alone [4].
Furthermore, advanced immunotherapeutic strategies
have also emerged, thus far without any significant success
[5]. The current evidence-based treatment recommenda-
tions for systemic therapy are well summarized in the work
from Olson et al. [6].
On review of among others recently reported ASTRO
[7] and ESTRO-ACROP guidelines for glioblastomas [8],
it would appear that substantial innovations with respect
to radiotherapy approaches such as target definition,
fractionation and planning as well as delivery techniques
are largely lacking, or at least these innovations do not
appear to find their way to current guidelines. From this
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unsubstantiated observation, the question arises whether
these components of modern radiotherapy have been an
integral part of past or current trials performed in glio-
blastoma patients.
In search of higher transparency and accessibility to
information, several institutions and groups have estab-
lished publicly available clinical trial registries. Trial
registration is being regulated with European and US
federal laws as well as international conventions (World
Health Organization, WHO) [9, 10]. Registration of all
interventional clinical trials is obligatory in the European
Union (EU) and the United States (US) and is required by
an international consortium of medical journal editors
[11]. ClinicalTrials.gov is the largest clinical trial registry
with over 200,000 registered trials and a high weekly
growth rate of new entries. The registration process and
its potential for an in-depth analysis of the clinical trials’
landscape is well described in the literature [12–16]. A
detailed description of registered protocol elements can
be found at the ClinicalTrials.gov website [17–19]. Due
to the nature of ClinicalTrials.gov trial submission process,
detailed information on past and present clinical trials can
be obtained using the ClinicalTrials.gov registry; usually
even more details than reported in the eventual peer-
reviewed publication.
The aim of the current study was to investigate in how
far radiotherapy innovations, in any aspect, have been an
integral part within the setup of past and current clinical
trials. In recent years, an abundance of phase I trials
have been initiated and completed, however, these trials
generally have focused on the addition of systemic com-
ponents in addition to standard forms of (radiotherapy
or surgery) treatment, and not as much on potential
innovations in the radiotherapy process. Therefore, we
restricted the current analysis to phase II and III clinical
trials for glioblastoma, reported in ClinicalTrials.gov in
recent years.
Materials and Methods
Data acquisition
The records of all 208,777 clinical trials registered at
ClinicalTrials.gov were downloaded on the 19th of
February 2016 and an SQL database was created to
enable further analysis. The following fields were
searched for glioblastoma-related keywords (glioblastoma,
astrocytoma grade 4 (iv), gliosarcoma, gbm): short title,
scientific title, conditions, a short summary and detailed
description. Using this search strategy, a total of 1.064 tri-
als were identified. We selected trials registered during the
time period from January 2005 to December 2015 for fur-
ther manual review. After exclusion of prematurely closed,
phase I or observational trials and trials not specific for
glioblastoma, 216 (20.3%) trials were selected for analysis.
The trial selection process is shown in Fig. 1.
Selected trials were divided into three groups: those con-
cerning newly diagnosed glioblastoma, those in recurrent
disease and finally trials where it was not specified or both
categories were included.
All registered interventions were classified according
to their specific role within the trial as part of the
standard treatment or the experimental approach. Date of
trial registration was taken into account. Systemic treat-
ments were categorized based on the resources available on
the following databases: www.drugbank.ca [20], National
Cancer Institute Dictionary of Cancer Terms (www.cancer.
gov), pubchem.ncbi.nlm.nih.gov as well as the Scopus
database, the PubMed Database, Google Scholar and
also through a generic internet search (Google search
engine). We classified systemic treatments into experimen-
tal and approved drugs based on the development status of
the specific therapy. Experimental drugs were annotated as
such if no previous indication was approved for commercial
usage from the United State Food and Drug Administration
(FDA). The investigational compounds were further classi-
fied based on their specific chemical subgroups according
to the World Health Organization ATC/DDD system
[21, 22]. By data unavailability, we manually classified
the selected drugs according to their chemical group, as
suggested in the WHO guideline [22]. Additionally, the
specific target receptors and the mechanism of action
were also searched and noted.
Radiotherapy, surgical procedures, and imaging pro-
cedures were classified according to their role in a
clinical trial as part of the standard treatment or as an
experimental intervention. If the procedure was in the
focus of a particular trial it was considered as an
experimental intervention. All surgical, as well as
radiotherapy approaches in the recurrent setting, were
considered experimental. Finally, all other interven-
tions that do not belong to the mentioned groups, but
were evaluated within a trial protocol were also con-
sidered as experimental.
In classifying the source of funding we used a modified
strategy based on the methodology previously described
in the work of Califf et al. [14].
Statistical methodology
Forecasting has been performed using the ARIMA
(Autoregressive Integrated Moving Average) model.
Based on Akaike information criterion (AIC), Root-
mean-square deviation (RMSE) and R squared, confi-
dence interval and logical outcome, the best model was
chosen. The time interval was 11 years divided into
quarters. We used the autoregressive order 1, difference
0 and moving average 1 [23]. Only non-seasonal struc-
ture was used. Forecasting was performed using R 3.3.0
statistical software.
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Results
Trial design characteristics are presented in Table 1 and
a general overview of the trials is shown in Table 2.
Academic centers (investigator-initiated trials) were
recorded as primary sponsors in 56.9% of the trials,
followed by industry 25.9%. Industry is the leading
source of monetary support in 44.4%, followed by aca-
demia in 25%. Other sponsors and sources of monetary
support are presented in Fig. 2.
The number of yearly initiated trials between 2005 and
2015 ranged between 1 and 11, and shows a slightly
positive trend (Fig. 3).
Fig. 1 Trials selection process diagram
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Systemic therapy
The majority of trials evaluate forms of systemic thera-
peutic approaches (n = 197, 91.2%). 43.7% of those were
in primary, 53.8% in recurrent and 2.5% in both disease
settings. Majority was phase II (87.8%), followed by
phase III (11.2%). 54.3% of trials on systemic therapy
was single arm without adequate comparator. In total
100 different molecular agents or biologicals were identi-
fied. Of those, 40 (40%) had been initially approved for
Table 1 Trials design data
Number Percent
Trial Phase
Phase 2 188 87.0
Phase 2/Phase 3 3 1.4
Phase 3 25 11.6
Number of Arms
1 107 49.5
2 83 38.4
≥3 13 9.7
NR 5 2.3
Sample Size
0 to 50 90 41.7
51 to 100 62 28.7
101 to 200 36 16.7
201 to 300 11 5.1
301 or more 16 7.4
NR 1 0.5
Interventional Model
Single Group Assignment 116 53.7
Parallel Assignment 92 42.6
Factorial Assignment 1 0.5
Crossover Assignment 2 0.9
NR 5 2.3
Treatment Allocation
Non-Randomized 47 21.8
Randomized 86 39.8
NR 83 38.4
Masking (Blinding)
Open Label 187 86.6
Single Blind 2 0.9
Double Blind 25 11.6
NR 2 0.9
Endpoint Classification
Safety/Efficacy Study 109 50.5
Efficacy Study 75 34.7
Safety Study 4 1.9
Bio-equivalence Study 1 0.5
Pharmacodynamics Study 1 0.5
Pharmacokinetics Study 1 0.5
NR 25 11.6
Primary Purpose of Trial
Treatment 207 95.8
Diagnostic 3 1.4
Health Services Research 1 0.5
Basic Science 2 0.9
Supportive Care 1 0.5
NR 2 0.9
Table 2 Trial characteristics
Number Percent
Disease Settings
1 5 2.3
2 96 44.4
3 115 53.2
Systemic Therapy as Investigative Intervention
0 19 8.8
1 95 44.0
2 84 38.9
3 17 7.9
4 1 0.5
Radiotherapy as Investigative Intervention
Not Used 121 56.0
Part of Standard Protocol 75 34.7
Experimental 20 9.3
Imaging as Investigative Intervention
Not Mentioneda 206 95.4
Experimental 10 4.6
Surgery as Investigative Intervention
Not Used 134 62.0
Part of Standard Protocol 71 32.9
Experimental 11 5.1
Trial Overall Status
Completed 93 43.1
Active, not recruiting 52 24.1
Not yet recruiting 13 6.0
Recruiting 58 26.9
Primary Sponsor Type
Industry 56 25.9
NIH 20 9.3
academy 123 56.9
collaborative group 17 7.9
Date of Registration
2005–2009 101 46.8
2010–2015 115 53.2
aMajority of trials do not mention imaging procedures in any contest.
Registered Data do not provide possibility to extract information about
utilization of imaging procedures as part of standard protocol
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indications other than glioblastoma or CNS malignancies.
Two (2%) were approved for glioblastoma or other CNS or
solid malignancies (carmustine, lomustine) and just one
(1%), namely temozolomide, for glioblastoma. Of the 57
(57%) compounds with investigational status 37 (37%) had
been investigated for other tumors and one for non-ma-
lignant conditions (1%). Nineteen (19%) substances were
developed specifically for the treatment of glioblastoma.
Classifying by drug type, 67 (67%) substances belong
to small molecules, 32 (32%) to biologicals and for one
(1%) substance we did not find any data. 42 (42%) com-
pounds were registered in the WHO ACT/DDD data-
base, with the most common group being protein kinase
inhibitors (n = 14, 14%), followed by “other neoplastic
agents” (n = 7, 7%), monoclonal antibodies (n = 5, 5%)
and lastly immunosuppressants and nitrosoureas (each
represented with 2 compounds (n = 4, 4%)). The last 12
registered products belong to different classes.
The remaining 58 (58%) compounds not registered in
the WHO ACT/DDD database most commonly evalu-
ated protein kinase inhibitors (n = 11, 11%), followed by
monoclonal antibodies (n = 13, 13%) of which 5 were
conjugated with toxins or radioisotopes and 6 (6%) vac-
cines. Alkylating agents, DNA repair inhibitors, and
other antineoplastic agents were each represented by 2
(4%) substances. Twenty-two (22%) substances belong to
other individual classes.
For 30 systemic therapeutic entities, we did not find
any specific target receptor or pathway. The most com-
monly researched targeted therapy aimed the EGFR re-
ceptor or its pathway (n = 11, 11%), followed by VEGF
(n = 8, 8%) and multi-TKIs (n = 5, 5%). An overview of
Fig. 2 Trials Primary Sponsors (a) and Probable Source of Monetary Support (b)
Fig. 3 Systemic therapy
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all the investigated systemic therapy agents is presented
in Additional file 1: Appendix 2. and Fig. 3.
Surgery
Primary glioblastoma In the primary setting, surgery
belonged to the investigational arm in four trials. Three
of these studies reported on the use of 5-aminolevulinic
acid (5-ALA) as a guidance help during surgery. One
single other study concentrated, among other endpoints,
on the cost effectiveness ratio between 5-ALA contrast
enhanced surgery versus placebo.
Recurrent glioblastoma Only a single trial
(NCT02394626 - RESURGE) concentrated solely on the
efficacy of surgery. RESURGE is a randomized phase II trial
with aim to evaluate value of surgical resection followed by
second line therapy compared with second line therapy
alone. The results should serve as a basis for larger phase
III trial. In 6 other studies, surgery was part of the com-
bined modality treatment for recurrent GBM in combin-
ation with chemotherapeutic strategies.
Radiotherapy Twenty trials (9.3% of all) evaluate RT as
experimental interventions. Of those only one (0.5%)
was phase III, namely NCT01450449 trial, sponsored by
the International Atomic Agency on short (5x5 Gy) vs.
standard course (15x2.7 Gy) of RT in elderly patients.
Primary glioblastoma Fifteen (6.9% of all) trials concen-
trated on radiotherapy in the primary setting, with four
(1.9%) trials exploring hypofractionated regimens, six
(2.8%) dose escalation, three (1.4%) target volume definition
(Subventricular zone RT, delineation with MRI vs. PET,
Whole Brain Low Dose RT) with one (0.5%) trial evaluating
the Boron-Neutron Capture Therapy and one (0.5%) com-
paring Intensity-modulated Radiotherapy (IMRT) versus
Intensity-modulated Proton Therapy (IMPT).
Recurrent glioblastoma Five (2.3% of all) trials were
evaluating the RT in the recurrent setting. Two (0.9%)
trials explored bevacizumab with or without radiotherapy
where in one trial RT was applied in form of radiosurgery.
One (0.5%) combined APG-101 with re-irradiation with a
dose of 36 Gy. One (0.5%) evaluates two hypo-fractionated
regimen (5x5 Gy vs 5x7 Gy), and one (0.5%) evaluates
delineation based on Amino-Acid PET with dose based
on MRI.
Imaging
Six trials evaluate imaging procedures in the primary
setting. Of those three evaluated MRI spectroscopy in
delineating the radiotherapy volume and two FMISO-PET
as a potential predictor. One trial directly compared MRI
versus FDG-PET in target volume delineation. Four trials
evaluated procedures in recurrent glioblastoma, one com-
paring MRI versus Amino acid-PET for target delineation,
one FET-PET for evaluating the response to bevacizumab,
one FMISO-PET, and MRI to evaluate the delivery of
bevacizumab and one investigating the value of MRI for
target delineation under bevacizumab treatment.
Other investigative treatments
Six trials explored the utilization of NovoTTF® device,
three Gliadel Wafer®, two transcranial magnetic stimulation,
and one the local application of cellular adoptive immuno-
therapy (Autologous Lymphocytes). One trial explored the
feasibility of molecular profiling with whole genome
sequencing and one the treatment of anxiety in patients
with glioblastoma.
The total number of trials initiated during the period
(2005–2015) and forecast (2016–2020) is presented in Fig. 4.
In regard to the several examined models, this model
showed the optimal AIC (203.52) and RMSE (2.194).
As presented in Fig. 2, in the next five years, it is ex-
pected that the number of studies show minor increase.
Similarly with the previous model, increasing trend is
observed regarding to number of phase II studies.
All trials evaluating surgery, radiotherapy, imaging and
other investigative treatments are listed in Additional file 2:
Appendix 1.
Discussion
In this work, we analyzed initiatives for trials for primary
and recurrent glioblastoma in the last 10 year period.
The total number of trials initiated yearly shows a slightly
positive trend, although this appears to be mainly driven
by a rise in the number of phase II trials, which constitute
the vast majority of trials in primary and recurrent glio-
blastoma, whereby no difference exists in terms of disease
setting (reccurent or primary). The most probable cause
for this high initiation of trials will probably be the failure
of previous early investigative treatments to show a clin-
ical significant advantage. Rather than starting more trials
unselectively, patients with (primary and recurrent) glio-
blastoma should be enrolled in early phase trials with
novel designs, such as basket trials where patient selection
is based on the genomic profile of the tumor rather than
anatomical or classical histological classification [24].
Funding in glioblastoma reflects the situation across
all clinical trials in oncology. Bradford et al. found that
41.8% of trials were funded primarily by the industry
[25], which corresponds with the 51.9% in our study. A
reason for concern should be the lack of industrial fund-
ing for research beyond forms of systemic therapy. The
industry has displayed a strong interest in sponsoring
trials for glioblastoma, and a variety of drugs are already
in the investigative pipeline. At the same time, surgery,
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radiotherapy, and imaging focused trials represent just a
small part of the glioblastoma clinical trial portfolio,
being investigated in the experimental part in only 9.7%
of all phase II/III glioblastoma trials. Research of the
aforementioned modalities is supported and driven only
from academic institutions while collaborative groups
or NIH support is sparse.
It appears that even in the academic community either
the interest, or the resources, for initiating of imaging,
radiotherapy or surgery research are limited. Of the 123
trials initiated by academic centers, only a minority
(19.5% of all GBM academic trials) evaluated these treat-
ment modalities in the experimental setting. Systemic
therapies are the focus of investigation in 66% of purely
academic trials, without registered or published external
financial support. It appears that medical oncologists are
leading the way in academic circles with innovative
approaches in the treatment of glioblastoma. Based on
the available data on ClinicalTrials.gov, we cannot assess
whether the required research funding originates from
third party sources such as research grants or private
donations or from the academic institution.
Trials evaluating exclusively glioblastoma may appear
rare when expressed in relative numbers (0.1% of all reg-
istered trials). Nevertheless, it is worth mentioning that
malignancies of the central nervous system represent a
high percentage of the overall cancer trials portfolio and
are more often in the research focus compared to other
tumor entities with often significantly higher incidences,
such as uterine, bladder and esophageal cancer [25].
Surgery in glioblastoma patients is of particular im-
portance and should be evaluated in detail. Trials in
the primary setting with surgery in focus, evaluate applica-
tion of 5-ALA tissue contrast and only one trial evaluates
resection optimization but from an economic perspective
(NCT01811121). Keeping in mind the poor prognosis of
glioblastoma and the predominance of failures at or near
the original tumor location, the role of maximal safe
surgical resection, lead to better outcome. There is solid
data showing that the brain plasticity is more flexible than
what was previously thought and therefore a more radical
resection could be feasible [26]. The extent of resection is
a known prognostic factor that influences survival. Lacroix
at al. has shown that the extirpation of 98% or more of
gadolinium-enhancing tumor mass was necessary to
achieve significant survival [27] and Sanai et al. concluded
that at least 78% of the enhancing tumor mass should be
resected [28]. Finally, Marko et al. concluded in a recent
analysis that any degree of resection is associated with a
survival benefit [29]. All three analyses are based on
Fig. 4 New trials per year. Panel a shows ARIMA forecast model for all evaluated trials. Panel b shows ARIMA forecast model for phase II trials only
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retrospective data and this topic deserves a prospective
evaluation. However, it seems that surgery does not
belong to the research focus of individual researchers,
industry or collaborative groups.
Next well established therapy for glioblastoma is radiation
therapy, where the standard dose for primary GMB in
younger patients with a good performance status is 60 Gy
[3]. For elderly patients hypofractionated radiotherapy
results in only a small benefit compared to the best
supportive care [30], with the most important prognos-
tic factor being age and the performance status [31].
Trials concentrated on specific radiotherapy questions
are mostly in phase II, with a small sample size and initi-
ated mainly through the academy.
As glioblastoma incidence is the highest in older
patients, the optimal therapy for this particular group is of
high interest. The currently available data suggest that sur-
gical resection may play an important role [32, 33]. Adju-
vant therapy is still a subject of investigation. Some data
suggest that a combination therapy (RT and temozolomide)
may cause excess toxicity [34, 35] and the current evidence
suggests that radiotherapy alone should be preferred in pa-
tients without MGMT promoter methylation (Methusalem
NOA-8 trial). Hypofractionation is an attractive option for
this particular patient group [36, 37]. In addition, there is
initial evidence that hypofractionated radiotherapy may
be combined with temozolomide and result in a better
outcome without the excess toxicity [38, 39]. The
NCT00482677 trial, could potentially provide definitive
answers. Here hypofractionation alone was compared
with hypofractionation and temozolomide in a population
older than 65 years. The preliminary findings of this trial
presented at ASCO 2016 showed a significant benefit for
the combined therapy schedule.
Alternative radiotherapy schedules, dose or volume
alterations could be of interest for the treatment of
glioblastoma regardless of patient age [40], although
we currently do not have high-quality prospective data.
Moderate dose escalation trials with conventional
radiotherapy methods failed to show an improvement
in the outcome [41]. Irradiation of the gross tumor
volume, even with higher doses, may be insufficient
owed perhaps to the infiltrative nature of glioblastoma
[42]. Higher dose escalation to the extended volume is
not feasible with the standard techniques due to the
close proximity of critical structures. The current body
of knowledge in regard to the benefits of dose escalation is
limited, but an intriguing report on dose escalation comes
from Tsien et al. Patients were treated with 66–81 Gy
delivered by IMRT with concurrent temozolomide. No
grade 3 toxicities were reported and a median survival
of 20.1 months was observed [43]. Several trials evaluated
dose escalation, with one of them deserving particular
mention: “MRSI Guided Dose Escalated Radiation in
Glioblastoma” (NCT02394665). Here investigators want
to utilize the capabilities of magnetic resonance spec-
troscopy imaging to detect in addition to the standard
MRI and high-risk area at risk of failure, the metabolically
active areas in newly diagnosed glioblastoma. Patients will
in a first phase undergo standard IMRT with an additional
stereotactic radiosurgical boost to the High-Risk Tumor
Volume as defined by 3D MRSI [44].
Furthermore, investigators try to evaluate volume alter-
ations together with dose de-escalation in the two Phase II
trials namely NCT01822275 and NCT02177578. The
tumor location in regard to the Subventricular Zone
seems to be of importance [45].
The combination of systemic therapies with radiation
as a chemosensitizing agent is certainly attractive. A notable
example is trial NCT01071837, where investigators com-
bined re-irradiation (36 Gy/2 Gy ED) with a CD95 ligand
inhibitor (APG101). Compared with re-irradiation alone,
the combination with APG101 shows a better 6-month
progression free survival and slightly better overall survival
[46]. But radiosensitization is not a well-understood process
and may be dependent on specific cell properties such as
genetic alterations. Some tumor cell lines can be resistant
to specific radiosensitizers depending on their molecular
profile [47]. In addition, glioblastoma evolves during the
time, and some passenger mutations may be respon-
sible for resistance development, either towards chemo
or radiotherapy.
Several trials are initiated in an effort to answer these
questions. The influence of radiotherapy on the clinical
course of the disease is certainly of the highest interest.
However, there are additional factors, beyond toxicity
and efficacy, that should be considered if radiotherapy is
applied. Some speculated that radiotherapy may even in-
crease the malignant potential of the tumors [48, 49].
This hypothesis seems to be especially valid for glioblast-
oma [50, 51]. Accelerated repopulation or selection of
more resistant cells is well recognized and described the
process in many tumor entities, and it may be that the
combination of geographical miss or an underdosing of
the volume of interest (recognized or not) plays a role.
Imaging modalities are rarely evaluated in the prospective
setting. The most commonly utilized experimental imaging
modalities are MRI spectroscopy and FMISO-PET-CT.
Besides, an FET-PET and Amino-Acid PET are used for
the delineation of radiotherapy treatment volume in re-
current glioblastoma. Imaging is used to predict treat-
ment response or to delineate the volume of interest.
All but one trial (NCT01507506) are in phase II with
low sample size. Further exploring of this area is neces-
sary. Furthermore, the size and role of the optimal radio-
therapy margins are also a matter of debate [52, 53]. This
is of particular importance in recurrent glioblastoma,
where we have significantly less experience. Evaluation of
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different imaging modalities in prospective settings may
play an important role in reducing this uncertainty [54].
Beside the target delineation, information gathered from
different sources, such as MRI, may be used for dose
calculations [55]. Furthermore, imaging is very interesting
for the evaluation of disease progression and response to
the therapy. It may be potentially used for the patient selec-
tion that will respond well to the systemic therapy [56, 57].
Although some research activity in imaging and radio-
therapy is present, this is not enough, especially if com-
pared with trials that evaluate systemic approaches.
Current margins of 1.5-2 cm and a RT dose concept for
GBM (60 Gy in 2 Gy fraction) are based on relapse pattern
analyses and toxicity profiles from a pre-systemic era. If
those are still necessary remains unclear and it will be
hardly possible to change current practice on a larger scale
without phase III data. However we did not detect any trials
to address these specific questions.
The majority of evaluated systemic therapies target
specific receptors or pathways. Beside protein kinase in-
hibitors, which represent the majority of evaluated drugs,
we detected over 20 different substances that try to target
other pathways and also 30 substances that do not aim a
specific pathway, mostly cytotoxic agents. Interesting find-
ings of this study is that 57% of the investigated substances
were not approved for marketing in any tumor entities, but
only 24% were initially intended for use in glioblastoma or
CNS malignancies. As the majority of those are sponsored
or supported by the industry, this indicates that glioblast-
oma is an attractive target even financially. A small benefit
in any of the endpoints may provide significant marketing
advantages and possibly profit, even when accounting the
low overall incidence of glioblastoma. Currently, there is
only two systemic therapies approved for glioblastoma two
from the cytotoxic group and one from the targeted group.
Glioblastoma is also an attractive target from a clinical trial
workflow perspective. Short term follow-up is certainly
reducing the overall cost of the trial [58].
It seems that immunotherapy is a promising treatment
modality and the combination with other options could
potentially have a synergistic effect. The potential of other
therapy forms to induce an immune response is also recog-
nized. One important preclinical study has already shown
that fractionated radiation may induce cell death [59]. This
should be evaluated further in order to better understand
the complex processes between the immune system and
CNS and tumor interactions.
Nevertheless results of phase II trials should always be
regarded cautiously. The problem of promising therapies
with consequent failures in pivotal studies is recognized.
An improvement of the trial design would be beneficial
to all involved parties [60].
At the time of analysis, the majority of trials were com-
pleted with 43.1% (n = 93) trials reported as completed
and 24.1% (n = 52) with achieved recruitment goals. Even
though the results for 39 (18.1%) trials were reported, only
16 of them were accompanied by their publication on
ClinicalTrials.gov. This could be attributed to several pos-
sible causes: Some of the published work was not captured
by an automatic search of the PubMed database [61]. The
second reason is the time required from finishing a trial to
final publication, in some cases exceeding 30 months [62].
Some trials will also never reach publication for unknown
reasons [63], with a significant proportion possibly attrib-
uted to negative result and as a result a lack of interest
either by the editors or the authors.
Limitations
The presented analysis is not without its limitations.
Some data might have been incorrectly registered in the
ClinicalTrials.gov. Moreover, we cannot exclude the
possibility that certain data were misclassified during
the selection and classification. In addition, the data
sets for all trials in the database are not always complete
and up-to-date. However, we took great care to minimize
these limitations: two authors (NC and AT) crosschecked
all trials identified and the trial selection steps.
Additionally, there may be a bias in in terms of number
of registered trials in recent years compared with early
period. We believe that our analysis is unique and import-
ant and that it provides researchers and clinicians with a
realistic picture of the future of glioblastoma treatment.
Conclusions
Investigation in glioblastoma is mainly driven or spon-
sored by the industry and medical oncologists, with the
majority of trials evaluating forms of systemic therapies.
Most of the trials are in phase II with just a few trials
ever reaching phase III. Imaging, surgery and radiation
therapy are heavily underrepresented treatment methods
in terms of investigations. Optimization in research port-
folio for glioblastoma is needed.
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